Drug intelligence / Profile preview

AN2811

Development stage: Preclinical
Lead developer: Beijing Anlong Biopharmaceutical
Modality: Small Molecules

Overview

AN2811 is a small molecule antagonist targeting the interleukin-4 receptor alpha (IL-4Rα), currently being developed by Beijing Anlong Biomedical. By binding to IL-4Rα, AN2811 modulates type 2 inflammatory responses, which are central to the pathogenesis of allergic diseases. The drug is primarily being investigated for the treatment of atopic dermatitis. As a small molecule alternative to monoclonal antibodies that target the same pathway, AN2811 may offer advantages in terms of administration and cost. It is currently in the IND-enabling stage of development.

Targets

IL4R (Interleukin-4 receptor alpha subunit)

Beyond the preview

Go deeper on AN2811.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AN2811.

Explore the full profile